Osteoporosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
For patients (people being studied for bone health concerns):
- Men or women receiving care at Saint-Etienne University Hospital who are at risk of osteoporosis (weak bones)
- People who have previously broken a bone due to weak or fragile bones
- People who have been recommended a bone density scan but have never had a fracture
- People with inflammatory joint diseases such as rheumatoid arthritis or spondyloarthritis (a type of spine inflammation)
- People with chronic kidney disease
- People with certain hormone or metabolic conditions, including overactive parathyroid glands, being very underweight (constitutional thinness), anorexia nervosa, obesity (BMI over 30), or significant muscle loss (sarcopenia)
- People with nerve-related conditions, including Parkinson's disease
For control participants (comparison group):
- People experiencing a recent episode of back or nerve pain (lasting less than one month) who have been taking steroid (corticosteroid) medication for less than one month
- People who have signed a written consent form agreeing to take part
Who may not be able to join:
- Anyone who has not signed a written consent form
- Control participants who have been taking certain bone-weakening medications for 6 months or more, such as anti-aromatase drugs, GnRH agonists, corticosteroids at doses of 5mg or more per day, or certain anti-epileptic drugs (carbamazepine, phenobarbital, phenytoin, primidone, or valproic acid) (confirm with trial site)
- Control participants who have previously broken a bone due to fragile or weak bones
- Control participants who are currently taking bone-strengthening medications such as bisphosphonates, teriparatide, or strontium ranelate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hubert MAROTTE, PhD, Centre Hospitalier Universitaire de Saint Etienne
Phone: (0)477127643
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
total volumetric mineral density by HR-pQCT; trabecular volumetric mineral density by HR-pQCT; Cortical volumetric mineral density by HR-pQCT; Describe number of trabeculae by HR-pQCT; Trabecular thickness by HR-pQCT; cortical thickness (mm) by HR-pQCT; trabecular separation by HR-pQCT; cortical porosity by HR-pQCT
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.